Immunoconjugates comprising tyrosine kinase inhibitors

Details Immunoconjugates comprising tyrosine kinase inhibitors Immunoconjugates comprising tyrosine kinase inhibitors

1996-11-22

1999-02-16

Feisee, Lila

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

5303917, 5303919, 530402, 530403, C07K 1702, C07K 1600, C07K 100, C07K 1400

Patent

active

058722238

ABSTRACT:
Immunoconjugates effective for treating cancers and autoimmune diseases in humans are provided which comprise a tyrosine kinase inhibitor linked to a ligand targeting a cell surface receptor which are specifically capable of inhibiting receptor associated tyrosine kinases.

REFERENCES:
patent: 5239062 (1993-08-01), Blattler et al.
Aldercreutz et al (Am. J. Clin. Nutr., 54:1093-1100) 1991.
Markowitz et al (Proc. AACR 31:(Abs. 2810)439 1990.
Cunningham, B. et al., "Synthesis and Biological Evaluation of a Series of Flavones Designed as Inhibitors of Protein Tyrosine Kinases" Anti-Cancer Drug Design, 7: 365-384 (1992).
Abrans, et al. Cancer, 74 (3 Supp), 1164-76 (1994).
Aldercreutz, et al. Lancet, 342, 1209 (1993).
Avila et al. Cancer Res., 54:2424-2428 (1994).
Cushman et al. J. Med. Chem., 37:3353-3362 (1994).
Cushman et al. J. Med. Chem., 34:798-806 (1991).
Eischen, et al. J. Immunol., 153, 1947 (1994).
Fukazawa, et al. Biochem. Pharm., 42:1661-1671(1991).
Levitzki, et al. Science, 267, 1782-1788(1995).
Liu, et al. Biochem. Pharmacol., 48, 1265-1272 (1994).
Migita, et al. J. Immunol.,153, 3457(1994).
Monti et al., AntiCancer Res., 14, 1221-1226 (1994).
Muthuswamy, et al. Mol. Cell Biol., 14:735-743(Jan. 1994).
Ogawara, et al. J. Antidiot.(Tokyo), 39, 606(1986).
Ottenhoff-Kalff et al. Cancer Res., 52:4773-8 (Sep. 1992).
Peterson et al. Prostate, 22, 335-345 (1993).
Reddy et al. Cancer Res., 52 3636-3641 (1992).
Scheuermann et al. PNAS USA, 91, 4048-4052 (1994).
Scholar et al. Cancer Letters, 87:159-162 (1992).
Toi et al. Eur. J. Cancer, 26:722-724 (1990)
Trail, et al. Science, 261:212(Jul. 1993).
Uckun, et al. Blood, 79:3369-3379 (Jun. 1992).
Uckun, et al. J. Exp. Med., 163:347(1986).
Uckun, et al. Science, 267:886-891 (Feb. 10, 1995).
Ullrich, et al. Cell, 61:203-212 (Apr. 1990).
WO-A-94 18345 Affymax Technologies, 18 Aug. 1994.
WO-A-94 26891 Schering Corp., 24 Nov. 1994.
WO-A-95 02187 Wellcome Found. Ltd., 19 Jan. 1995.
WO-A-95 07348 Imclone Systems Inc., 16 Mar. 1995.
Bolen et al, FASEB J. 1992, 6:3403.
Yamanashi et al Science, 251: 192, 1991.
Ausubel et al Current Protocols in Mol Bio, Green Pub. Assn, 1992, pp. 11.1.1-111.1.2.
Waddick et al, Radiation Res, 1993, 136:313.
Uckun et al PNAS, USA, 90: 252, 1996.
Uckun et al JBC, 1993, 268: 21172.
Hird et al, Genes & Cancer, P Carney & K Sikora Eds, 1990, John Wiley Ltd, pp. 183-189.
Osband & Ross, Immunol Today, 1990, 11:193-195.
Caneuari et al, (Annals of Oncol, 1994, 5:698-701).
Ariyama et al JBC, 1987, 262:5592.

Affiliated with

Also associated with

Rating

Immunoconjugates comprising tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoconjugates comprising tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoconjugates comprising tyrosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2063283